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Abstract
Background: In the last few years, the study of microparticles (MPs) - submicron vesicles released from cells upon
activation or apoptosis - has gained growing interest in the field of inflammation and in infectious diseases. Their
role in the human malaria parasite Plasmodium vivax remains unexplored. Because acute vivax malaria has been
related to pro-inflammatory responses, the main hypothesis investigated in this study was that Plasmodium vivax
infection is associated with elevated levels of circulating MPs, which may play a role during acute disease in non-
immune patients.
Methods: Plasma MPs were analysed among thirty-seven uncomplicated P. vivax infections from an area of
unstable malaria transmission in the Brazilian Amazon. The MP phenotype was analysed by flow cytometry using
the classical MP marker, annexin, and fluorochrome-labeled monoclonal antibodies against specific cell surface
markers. The frequencies of plasma MPs in P. vivax patients (n = 37) were further compared to malaria-unexposed
controls (n = 15) and ovarian carcinoma patients (n = 12), a known MPs-inducing disease non-related to malaria.
Results: The frequencies of plasma circulating MPs were markedly increased in P. vivax patients, as compared to
healthy age-matched malaria-unexposed controls. Although platelets, erythrocytes and leukocytes were the main
cellular sources of MPs during vivax malaria, platelet derived-MPs (PMPs) increased in a linear fashion with the
presence of fever at the time of blood collection (b = 0.06, p < 0.0001) and length of acute symptoms (b = 0.36,
p < 0.0001). Finally, the results suggest that plasma levels of PMPs diminish as patient experience more episodes of
clinical malaria (b = 0.07, p < 0.003).
Conclusions: Abundant circulating MPs are present during acute P. vivax infection, and platelet derived-MPs may
play a role on the acute inflammatory symptoms of malaria vivax.
Background
Plasmodium vivax is the most widespread Plasmodium
species being responsible for up to 390 million clinical
cases each year [1,2]. For long, P. vivax infection was
considered a benign and self-limited disease, especially
when compared to the burden of Plasmodium falci-
parum infection. Recent studies from Indonesia, Papua
New Guinea and India have, however, highlighted the
association between vivax malaria and life-threatening
manifestations, such as respiratory distress, severe anae-
mia, and neurological manifestations with coma [3-5],
placing P. vivax infection in a higher status as a global
health concern.
An additional neglected effect of the “benign” P. vivax
infection concerns its poorly explored pathogenesis. While
a large bulk of literature on the immunological and
inflammatory patterns of falciparum malaria is available,
the pathogenesis of vivax malaria was not submitted to
such scrutiny. It is, nevertheless, intriguing that P. vivax
infection triggers fever with a lower peripheral parasitae-
mia [6-8]. The few studies that had addressed the patho-
genesis of vivax malaria had shown that P. vivax infection
induces greater host inflammatory responses compared to
P. falciparum malaria [9-11] with pro-inflammatory cyto-
kines levels being closely associated with disease severity
in some studies [10-13]. Hence, the different clinical pre-
sentations of vivax malaria infection may be related to the
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any medium, provided the original work is properly cited.intensity of pro-inflammatory responses. In this regard, the
search for sensitive and predictive inflammatory biomar-
kers in vivax malaria may enhance early detection of
severe cases.
Cellular microparticles (MPs) - submicron (< 1 μm)
membrane vesicles released from cells into the blood
stream in response to a variety of stimuli, i.e. cell activa-
tion, stress, serine proteases, pro-inflammatory cytokines
and apoptosis, have emerged as potential inflammatory
biomarkers as elevated levels are found in plasma during
many diseases of inflammatory etiology [14]. Conse-
quently, this heterogeneous population of small, mem-
brane-coated vesicles has been used as sensitive markers
of diverse process, such as inflammation, coagulation,
vascular function and apoptosis. In addition, MPs are
important carriers of membrane components or bioac-
tive molecules [15] being involved in a series of “gain of
function” phenomena [16]. As an example, MPs derived
from activated platelets have been shown to play a role
on the pathogenesis of P. falciparum cerebral malaria by
transferring platelet antigens to the surface of iRBCs
and dramatically enhancing their cytoadherence to
endothelial cells within brain micro vessels [17,18]. MPs
have also been shown to contribute to inflammation
during P. berghei malaria by inducing potent activation
of macrophages [19]. However, their role in vivax
malaria pathogenesis has not been investigated.
T h em a i nh y p o t h e s i st ob ei n v e s t i g a t e dh e r ei st h a t
P. vivax infection is associated with elevated levels of cir-
culating MPs of different cellular origins, and those MPs
p l a yar o l ei nP. vivax induced inflammation. For this
purpose, the phenotype of circulating MPs in plasma
from P. vivax malaria patients in a hypoendemic area of
the Brazilian Amazon was assessed. As control, the
plasma MP phenotype from healthy malaria-unexposed
donors and patients with ovarian carcinoma, a known
MPs-inducing disease non-related to malaria, was simul-
taneously investigated. The results showed that platelet
(PMPs), erythrocyte (EMPs) and leukocyte (LMPs)
derived-MPs are significantly increased in plasma from
P. vivax patients as compared to healthy donors. Inter-
estingly, the frequencies of annexin V/CD41a double-
positive MPs (PMPs) were associated with the length of
acute illness and the presence of fever at the time of
blood collection. The results presented here comprise
the first evidence of the presence of MPs during vivax
malaria and offer a new tool for the study of the pro-
inflammatory patterns of P. vivax infection.
Methods
Study site and subjects
This study was conducted between January and November
2008, in the outpatient clinic of the Tropical Medicine
Center of Porto Velho (CEMETRON), the capital of
Rondônia State, Brazilian Amazon area. In the Amazon
area, malaria is mainly an occupational disease, with popu-
lation at risk largely represented by adult males. Low rates
of transmission occur throughout the year with large dom-
inance of vivax over falciparum malaria [20]. The main
vector is Anopheles darlingi and the number of infective
bites associated with malaria is estimated to be between
2 to 10 per inhabitant per year [21].
Individuals who sought care at CEMETRON and
whose thick blood smear was positive for P. vivax, were
invited to participate in the study. Selected volunteers
were all negative for P. falciparum and/or Plasmodium
malariae infection by both microscopic examination
and a nested-PCR, carried-out latter. Thirty-seven
patients, aging 15 to 66 years, were enrolled in the study
after the written informed consent, in accordance with
guidelines for human research, as specified by the Brazi-
lian National Council of Health (Resolution 196/96).
Antimalarial and supportive therapies were given
according to standard protocols.
Clinical and demographical data were acquired through
a standardized questionnaire, and the haematological pro-
file was assessed by automated complete blood count car-
ried-out at CEMETRON’s hematology facility. Table 1
summarizes demographic, epidemiological, parasitological
and hematological data of P. vivax infected-volunteers.
In the studied area, subjects were migrants from
malaria-free areas. Consequently, their ages do not
necessarily correlate with malaria exposure. Cumulative
exposure to malaria was, therefore, based on self-
reported number of lifetime malaria episodes. As their
previous malaria experience showed a variable number
of infections, extreme values and the possibility of recall
bias were avoided by categorizing patients into three
groups: i) five or less previous malaria episodes (PME);
ii) 6 to10 PME; and ii) more than 10 PME. Venous
blood was obtained from patients on admission, and in
those with fever (above 37.5°C) at the time of blood col-
lection. In five patients it was possible to take additional
samples, during convalescence, on day 7 and 21 after
treatment. Plasma samples from fifteen age-matched
malaria-unexposed donors we r eu s e da sb a s e l i n ec o n -
trol. As MPs positive samples plasma from 12 patients,
aging 45 to 65 years, diagnosed with ovarian carcinoma,
as it has been shown that cancer cells from this highly
lethal gynaecological malignancy can release MPs [22].
Purification of MPs from plasma
MPs were prepared as described elsewhere [17,19]. Briefly,
Citrated blood (0.5 mL) was centrifuged at 1,500 × g for
15 min, and plasma was then cooled to -20°C before sto-
rage at -80°C. Samples were further centrifuged at 13,000
xgfor 3 min to obtain platelet-free plasma. The latter was
diluted 1:3 in citrated PBS containing heparin and
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MP pellet was then resuspended in 1× annexin V binding
buffer (BD Biosciences, California, US).
Flow cytometry assays
Unless otherwise stated, all reagents and mAbs used in
the Flow cytometry experiments were from BD Bios-
ciences. MPs isolated from plasma were gated (R1) based
on their forward (FSC) and side (SSC) scatter distribution
as compared to the distribution of synthetic 0.7 - 0.9 μm
SPHERO™ Amino Fluorescent Particles (Spherotech Inc.
Libertyville, Illinois, US) (Figure 1A). Taking into account
the presence of PS residues in MPs surface, events pre-
sent in R1 were accessed for their positive staining for
annexin V (BD Bioscience) - a classical marker for micro-
particles - using PE-conjugated monoclonal antibodies
(mAbs) (Figure 1B). Mouse IgG PE conjugated isotype
control mAbs were used to properly place gates. Annexin
V
+ events gated within the R2 region were further
assessed for immunolabeling with FITC-conjugated
mAbs against the cell markers CD41a (platelets), CD144
(endothelial cells), CD235a (erythrocytes), CD45 (leuko-
cytes) and CD14 (monocytes) or the correspondent
mouse IgG FITC-conjugated isotype control mABs. The
samples were analysed in a Flow Cytometry FACSCalibur
(Becton-Dickinson, California, US). Over 100,000 events
were acquired on each sample, to reach at least 2,000
events within the MPs gate.
Quantification of plasma MPs levels
To confirm if the absolute numbers of plasma MPs were
different between malaria patients and healthy donors, as
well as to determinate the numbers of plasma MPs per
microliter (MPs/μl), the cytometer was set to operate at a
high flow rate setting for 60 seconds for each sample. The
number of MPs/μl of plasma was calculated as described
elsewhere [18]: MPs/μl = (N × 400)/(60 × 100), in which
N is the number of events, 400 is the total volume of in
the tube before analysis, 60 is the sample volume analysed,
and 100 is the original volume of MPs suspension.
Statistical analysis
Data were analysed using Graph pad Instat 4.0 and SPSS
15.0 statistical software. Differences in the means of the
frequencies (double staining for annexin V and cell mar-
kers) between groups were analysed using two-tailed
student’stt e s to rM a n n - W h i t n e yw h e nd a t ad i dn o tf i t
a Gaussian distribution. The log-transformation of data
was applied for situations where variances normality
assumptions failed followed by linear regression to
investigate the association between the clinical para-
meters and MPs levels. Pairwise correlations were evalu-
ated with Pearson’s correlation coefficient r. Multiple
linear regression models with stepwise backward dele-
tion were built to describe independent associations
between covariates (fever, age and number of previous
malaria episodes) and the presence of PMPs. A P value
< 0.05 was considered to be statistically significant. For
illustration purpose (as shown in Table 1 and Figure 2)
the patients were categorized into sub-groups according
to their body temperature, the numbers of previous
malarial episodes, length of symptoms (in days), and
days since last malarial episode.
Results
Platelet, erythrocyte and leukocytes are the main sources
of plasma MPs during acute P. vivax malaria
The phenotype of plasma circulating MPs during acute
vivax malaria was investigated, with specific mAbs for
cell markers i.e. CD41a, CD235a, CD45, CD144 and
CD14 were used to discriminate the cellular sources of
Table 1 Characteristics of the thirty seven uncomplicated
Plasmodium vivax patients
CHARACTERISTICS
Gender, male:female 2.7:1
Median Age, years (range) 36 (15–66)
N° of previous malaria episodes, n (%)
≤ 5 19 (51.3)
6 – 10 13 (35.1)
> 10 5 (13.5)
N° of days of acute illness, n (%)
≤ 2 10 (26)
3 – 5 19 (51.3)
> 6 8 (21.6)
Symptoms in the last 3 days, n (%)
Fever 37 (100)
Headache 33 (89.1)
Chills 35 (94.6)
Myalgia 32 (86.4)
Anorexia 24 (64.8)
Nausea 13 (35.1)
Diarrhoea 7 (18.9)
Vomiting 6 (16.2)
Dyspnea 4 (10.8)
Parasitaemia, parasites/μl of blood, n (%)
≤ 500 10 (27.0)
500 – 10,000 10 (27.0)
> 10,000 17 (45.9)
Body temperature (
oC)
≤ 36 8 (21.6)
37 – 37.8 14 (37.8)
> 37.8 15 (40.5)
Haemoglobin levels g/dL, median (range) 13.26 (9.7–16.6)
Platelet counts ×1000/mm
3, median (range) 115 (53–208)
Leukocyte counts ×100/mm
3, median (range) 52 (23–117)
Haematocrit %, median (range) 41 (32.2– 50.6)
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+ MPs. The percentages of annexin V
+ MPs
stained for each cell marker was compared between
samples from P. vivax malaria patients, healthy donors
or samples from a MPs-induced disease non-related to
malaria (Figure 1C).
The frequency of platelet (PMPs) (p < 0.0001), ery-
throcyte (EMPs) (p = 0.0023) and leukocyte derived-
microparticles (LMPs) (p = 0.0087) were significantly
increased in plasma samples from malaria patients as
compared to healthy donors. The increased levels of
Figure 1 Identification of plasma MPs. (A) MPs isolated from plasma were gated (R1) basedo nt h e i rf o r w a r d( F S C )a n ds i d e( S S C )s c a t t e r
distribution as compared to 0.7 - 0.9 μm synthetic Nile Red microparticles (grey dots). (B) Events present in R1 were accessed for their annexin V
positive staining using PE-conjugated mAbs. Mouse IgG PE-conjugated isotype control mAbs were used to place gates accurately (R2). (C) FITC
immunolabeling for the cell markers CD41a (platelets), CD144 (endothelial cells), CD325a (erythrocytes), CD45 (leukocytes) and CD14 (monocytes)
was further assessed within annexin V
+ gated events (R2) and were compared in plasma samples from healthy donors, P. vivax malaria and ovary
carcinoma patients (MPs-induced disease). Boxes represent median and interquartile interval, whiskers represent the 10 and 90 percentiles. Means
were compared using the Mann-Whitney two-tailed test. A p value < 0.05 was considered significant.
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lute number of MPs per μl of plasma was calculated
(additional file 1). As expected, the frequencies of PMPs
and EMPs, but not LMPs, were also significantly
increased in plasma from patients with ovarian carci-
noma (p < 0.05). These results suggest that platelets,
erythrocytes and leukocytes are the main source of
plasma circulating MPs during acute P. vivax malaria
and its presence may be associated with inflammation.
Plasma MPs associate with acute malaria symptoms
To investigate the role of MPs in the pathogenesis of
vivax malaria, potential factors that could be associated
with the presence of circulating MPs in acute P. vivax
infection were analysed, including demographic, clinical,
haematological and parasitological parameters. No asso-
ciation was found between levels of MPs and haemato-
logical (haemoglobin levels, haematocrit, platelet or
leukocyte counts) or parasitological data. Of note, posi-
tive linear trends were observed between the presence
of fever at the time of blood collection and the fre-
quency of PMPs in plasma (b = 0.06, p < 0.0001) (Figure
2A). Significant association was also observed between
higher frequencies of PMPs and prolonged malaria
symptoms, estimated here by number of days with
acute illness (b =0 . 3 6 ,p < 0.0001)( F i g u r e2 B ) .
Figure 2 Platelet derived MPs (PMPs) correlate with fever and length of symptoms of ac u t em a l a r i aa n dm a yb ei m p a c t e db y
cumulative clinical malarial episodes. P. vivax malaria patients were categorized according to their body temperature (°C) (A); prolonged
symptoms (B); cumulative malarial episodes (median 5, range 0 - 60) (C); and the time since last malarial episode (D). Boxes represent median
and interquartile interval, whiskers represent the 10 and 90 percentiles. Data were transformed into neperian logarithm before applied to linear
regression analysis. Positive linear trends were observed between the frequency of PMPs in plasma and presence of fever (above 37.5°C) at the
time of blood collection (b = 0.06, p < 0.0001), length of malaria symptoms, estimated here by number of days with acute illness (b = 0.36,
p < 0.0001), and previous clinical malaria episodes (b = 0.07, p < 0.003).
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last four or more days before seeking care at CEME-
TRON had significant higher levels of PMPs in plasma
when compared to patients reporting more immediate
symptoms. Apparently, the levels of PMPs in plasma
diminish as previous clinical malaria episodes increases
(b = 0.07, p < 0.003) (Figure 2C). No significant associa-
tion was found between PMP levels and days elapsed
since last malarial episode (Figure 2D).
Although manifestation of acute malaria such as fever
can be influenced by different factors including host age
and immunological background - evaluated here by pre-
vious malaria experience - multiple linear regression
models confirmed the independent association between
fever and microparticles, as well as length of symptoms
and microparticles (p < 0.001).
Plasma MPs levels decrease after anti-malarial
chemotherapy
In five P. vivax patients, plasma MPs levels were
assessed 7 and 21 days after anti-malarial chemotherapy.
The levels of plasma MPs remain unchanged at 7 days
post infection; however, as shown in Figure 3, the levels
of plasma MPs decreases after 21 days post treatment.
Discussion
Despite increasing evidence of multidrug-resistant
P. vivax associated with severe and fatal disease, little is
known about its pathogenesis. This study provides the
first evidence that microparticles (MPs) from leukocytes,
platelets, and erythrocytes are significantly increased in
plasma from acute P. vivax malaria patients. These
results are consistent with the observation that active,
non-cytokine, factors are present in paroxysm plasma
from non-immune patients with acute P. vivax infec-
tions [23,24]. As some of the active components in par-
oxysm plasma are lipids, of unknown nature, and,
importantly, are present in particulate form [24], MPs
could contribute to P. vivax paroxysms. However, at this
time, it is not possible to conclude on the role of MPs
during paroxysm, because it remains as undefined com-
plex phenomenon, which involves several components,
including host-derived cytokines [24].
As virtually all cell types can release MPs, the pre-
sence of MPs of different origins circulating during
acute P. vivax malaria is not unexpected. It rather sug-
gests that different cell types are activated and partici-
pate in the myriad of inflammatory processes induced
by P. vivax parasites/infection. In fact, these data are in
concordance with a recently published study reporting
that children infected with P. falciparum presents high
levels of circulating MPs, including those from platelet,
erythrocytes, endothelial cells and leukocytes [25]. In
these infected Cameroonian’s children, MPs levels
returned to normal when the patients were cured. This
results are in line with the observations described here
with P. vivax, and by others with P. falciparum [17],
which shown that the levels of MPs significantly
decrease after 19 - 21 days post treatment.
In the present study, elevated levels of platelet-derived
microparticles (PMPs) were associated with clinical
manifestation of disease, such as fever and prolonged
time with malaria symptoms. At this time, the signifi-
cance of this finding in P. vivax infection is not clear,
but they are of particular interests as both platelets [26]
and PMPs [18] have been shown to play a role in the
pathogenesis of malaria caused by P. falciparum.M o r e -
over, MPs have been shown to be mediators of the
inflammatory process that occur during infection with
Plasmodium berghei in mice [18]. Recently, Boilard and
colleagues [27] provides strong evidence for the patho-
genic role of PMPs, confirming their contribution as
“incendiary devices” in the conflagration of a hot, swol-
len, and painful rheumatoid joint.
Although evidence for a role of microparticles in human
malaria diseases at present is still only limited, new
evidence is accumulating rapidly to support this theory.
In Cerebral Malaria, the most severe complications of
P. falciparum infection, PMPs levels significantly
correlated with coma depth and thrombocytopenia [25].
Consequently, these authors have been proposed cell-
specific MPs as biological marker for cerebral dysfunctions
Figure 3 Plasma MPs levels decrease after anti-malarial
chemotherapy. Levels of platelet (PMPs), erythrocyte (EMPs) and
leukocyte derived-MPs (LMPs) were quantified in plasmas from five
patients at the acute phase of P. vivax infection (0) and after 21
days of anti-malarial chemotherapy. MP levels were calculated and
expressed as number/μl of plasma as detailed in Methods. Statistical
analyses were performed using the two-tailed paired t-test. A
p value < 0.05 was considered significant.
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MP production as a new therapeutic target against cere-
bral malaria.
As in P. falciparum PMPs facilitate cytoadherence of
iRBCs to brain endothelial [18], it is reasonable to spec-
ulate that, similarly, they might be involved in the
underlying mechanisms driving pulmonary vascular
sequestration in P. vivax malaria as suggested by Anstey
et al [7]. However, as cytoadherence is not a common
feature of vivax-infected RBCs and evidences for their
microvascular accumulation is, at best, modest [28], it is
conceivable that PMPs may be merely an epiphenome-
non of the pro-inflammatory response previously
observed in vivax malaria [12,29-31]. Further studies will
be required to investigate if circulating PMPs from
P. vivax patients may act either as biomarker or mediator
of inflammation/disease (or both).
A potential limitation of the statistics analysis per-
formed here was that multiple comparison were rea-
lized, aiming to find possible associations between MPs
and clinical/biological parameters; however, it should be
take in consideration that these significant findings were
hypothesis-generating, and, consequently, its represent a
realistic interpretation of the facts. In addition, multiple
linear regression models confirmed the independent
association between fever and length of symptoms with
platelets-derived microparticles.
An interesting finding was the presence of leukocyte
and erythrocyte derived-MPs during acute P. vivax
malaria. The role of leukocytes in malaria pathogenesis
is still not fully understood; nevertheless, it has been
shown that these cells are the main source of pro-
inflammatory cytokines, especially TNFa which is highly
pyrogenic [32]. The presence of MPs derived from these
cells provides evidence for their activation in acute vivax
malaria. Perhaps, an attractive field of study is to investi-
gate whether or not EMPs might contribute to the dis-
tinct erythrocyte destruction commonly observed in
vivax malaria [33]. Although severe anemia can be pro-
duced by both P. vivax and P. falciparum infections,
malariotherapy studies have shown greater destruction
of non-infected RBCs per infected erythrocyte in P.
vivax as compared to P. falciparum malaria [33].
Accordingly, in the present study, the frequency of ery-
throcyte derived MPs in plasma was not associated with
parasitaemia. Actually, the absence of correlation
between MPs and parasitaemia is not unexpected,
because in the Brazilian Amazon area the wide range of
parasitaemia found in P. vivax infection does not enable
to conclude on the value of this variable as determinant
of severity [34].
While it is not possible at this time to characterize the
mechanism by which MPs might be involved in the
pathogenesis of P. vivax m a l a r i a ,t h ed a t as h o w nh e r e
raise important questions on the role of cell derived
MPs in malaria pathogenesis revealing a fruitful area for
investigation. Thus, the potential of circulating cell
derived-MPs as non-invasive inflammatory marker of
P. vivax morbidity is likely.
Conclusions
This paper describes the initial attempts made at char-
acterization of the MP phenotype in vivax malaria. It is
shown here that the plasma levels of platelet, erythro-
cyte and leukocyte-derived MPs are increased during
acute uncomplicated vivax malaria. In P. vivax patients
platelets derived-MPs were significantly correlated with
fever and length of symptoms. Elucidation of the micro-
particles composition and the mechanisms involved in
exertion of their effects could contribute to additional
intervention strategies against malaria.
Additional material
Additional file 1: Quantification of platelet, erythrocyte and
leukocyte derived-MPs levels in plasma from P. vivax patients,
before and after antimalarial treatment. Plasma levels of platelet,
erythrocyte and leukocyte derived-MPs were calculated as described in
Methods; results are expressed as MPs/μl. The absolute numbers of
plasma MPs was compared among healthy donors and P. vivax malaria
patients. Statistical analysis was performed using the Mann-Whitney two-
tailed test. A p value < 0.05 was considered significant.Supplementary
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